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Background: In both women and female dogs, the most prevalent type of malignant neoplasm is the
spontaneous mammary tumor. In dogs, half of these are malignant. The treatment of choice for the canine patients
is surgical mastectomy. Unfortunately, it often fails in high-risk, locally invasive mammary tumors as of during the
time of the surgery the micro-metastases are present. Moreover, there are neither large studies conducting to prove
of the benefit from the chemotherapy in dogs nor established chemotherapy treatment protocols available.
Additionally, the effectiveness of each individual chemotherapeutic agent and drug resistance of canine mammary
cancer have not yet been characterized. That has become the aim of our study, to assess the expression of PGP,
BCRP, MRP1 and MRP3 in canine mammary cancer cell lines and to investigate their role in cancer resistance to
vinblastine, cisplatin and cyclophosphamide with using RNAi approach.
Results: The results suggested that in canine mammary cancer, the vinblastine efflux was mediated by PGP and
MRP1 proteins, cisplatin efflux was mediated by all four examined efflux pumps (PGP, BCRP, MRP1 and MRP3),
whereas cyclophosphamide resistance was related to BCRP activity. RNAi silencing of these efflux pumps
significantly decreased IC50 doses of the examined drugs in canine mammary carcinoma cells.
Conclusions: Our results have indicated the treatment of cells involving use of the siRNA targeting efflux pumps
could be a beneficial approach in the future.
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In both women and female dogs, the most prevalent
type of malignant neoplasm is the spontaneous mam-
mary tumor. In dogs, half of these are malignant. There
is a threefold incidence in the canine, with middle aged,
non-spayed female dogs being the most affected [1,2].
The early ovariectomy is thought to reduce the risk of
mammary cancer development [3], however, the high
morbidity and mortality rate due to ineffective treatment
strategies makes this problem as being still actual. The
treatment of choice for the canine patients is surgical
mastectomy. Unfortunately, it is often recognized -* Correspondence: magdalena_krol@sggw.pl
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distribution, and reproduction in any mediumunsatisfactory as in case of invasive cancer at the time of
surgery the micro-metastases are present. Moreover,
clinical studies reveal that after regional mastectomy
77% of dogs developed a new malignancy [4]. There are
neither large studies conducting to prove to the benefit
of chemotherapy in dogs nor established chemotherapy
treatment protocols available. Moreover, the effective-
ness of each individual chemotherapeutic agent and drug
resistance of canine mammary cancer have not yet been
characterized. The available data is conflicting, possibly
due to the small number of studies performed, or the
insufficient number of dogs used in these studies. Some
veterinarians adapt human chemotherapy protocols;
however these treatment modalities are often unsatisfac-
tory due to similarities observed in recurrence time, time
to metastasis and overall survival [5-7].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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by the activity of efflux pumps that belong to the ABC-
transporters super family. The most important in breast
cancer are: PGP (P-glycoprotein), BCRP (Brest Cancer
Resistance Protein), MRP1 (Multridrug resistance Pro-
tein 1) and MRP3 (Multidrug Resistance Protein 3). For
example, in human cancer over-expression of PGP is
linked to resistance to vinca alkaloids, anthracyclines,
epipodophyllotoxins and also tubulin polymerizing drugs
whereas MRP1 is responsible for resistance to vincristine
and vinblastine, methothrexate, anthracyclines, etopo-
side, paclitaxel and irinotecan [8,9]. Unfortunately, ex-
pression of efflux pumps and their specific substrates
have not been assessed in dogs yet. There is just one
document published showing that BCRP can fully pro-
tect canine mammary cancer cells against doxorubicin
[10].
That is why the aim of our study was to assess expres-
sion of PGP, BCRP, MRP1 and MRP3 in five canine
mammary cancer cell lines and to investigate their role
in cancer resistance to vinblastine, cisplatin and cyclo-
phosphamide which are used in breast cancer treatment
[11,12]. The examined drugs were selected based on the
available data in the field of veterinary oncology. They
presented positive results of cisplatin and cyclopho-
sphamide treatment in canine mammary cancer [5,7]
whereas vinblastine was selected due to its general toler-
ance [13]. Moreover, these anticancer agents belong to
various groups, thus we used them to observe efflux
pumps activity during treatment with drugs from
different groups.
We also treated canine mammary cancer cells with
siRNAs specific for these efflux pumps to knock-down
their expression. Treatment of cancer cells by using
classical inhibitors of efflux pumps often fails [8,9], thus
we used a novel approach to reduce their activity.
Our results have pointed out that treatment of patients
with the supportive use of the siRNAs specific for efflux
pumps may help with improving results of chemother-
apy. Despite the useful function of RNAi therapeutics
for disease treatment, it, yet - still requires the develop-
ment of clinically suitable, safe and effective drug deliv-
ery vehicles, there are some promising data from
ongoing clinical trials that give hope for their practical
application in the future [14].
Methods
Cell lines
The cell lines used for the study have been previously used
in other published research [14-18]. Two canine mam-
mary adenocarcinoma cell lines (CMT-W1, CMT-W2),
anaplastic cancer cell line (P114), simple carcinoma cell
line (CMT-U27) and spindle-cell mammary tumor cell
line (CMT-U309) had been examined. Cells were culturedunder optimal conditions: in RPMI-1640 medium
enriched with 10% (v/v) heat-inactivated fetal bovine
serum (FBS), penicillin-streptomycin (50 iU mL–1), and
fungizone (2.5 mg mL–1) (reagents obtained from Sigma
Aldrich, USA), in an atmosphere of 5% CO2 and 95%
humidified air at 37°C.
siRNA transfection
The siRNA transfection procedure used in canine mam-
mary cancer cells was described in details in our pre-
viously published studies [19-21]. The cell density,
transfection reagent toxicity and transfection efficacy
were optimized according to the procedure described in
our previous manuscript: [19]. The canine (Canis lupus
familiaris) pgp, bcrp, mrp1 and mrp3 sequences were
obtained from Gene Bank with accession numbers:
NM_001003215, DQ222459.1, NM_001002971, XM_54
8204.2, respectively. The siRNA duplexes were designed
by http://www.sigmaaldrich.com/life-science/custom-olig
os/sirna-oligos/sirna-design-service.html. The results were
confirmed using two independent algorithms: Dharmacon
(OligoWalk) and Ambion and two duplexes were used for
further experiments (obtained from Sigma Aldrich)
(Table 1). For each gene silencing the mixture of both du-
plexes was used (30 pmol + 30 pmol). All the experiments
with transfected cells were conducted 24–48 hrs after the
transfection.
Reverse-transcriptase qPCR
Total RNA was isolated using a Total RNA kit (A&A
Biotechnology, Poland) according to the manufacturer‘s
protocol. Isolated RNA samples were dissolved in
RNase-free water. The quantity of isolated RNA was
measured using NanoDrop (NanoDrop Technologies,
USA). The mean concentration of RNA was 173 ng/μl,
and A260/280 ratio was between 1.8 and 2.0. The sam-
ples with adequate amounts of RNA were treated with
DNaseI to eliminate DNA contamination. The samples
were subsequently purified using RNeasy MiniElute
Cleanup Kit (Qiagen). Finally RNA samples were ana-
lyzed on a BioAnalyzer (Agilent, USA) to measure final
RNA quality and integrity. Only RNA with RIN (RNA
Integrity Number) > 9 was used for the further analyses.
Primers used to detect the expression of pgp, bcrp, mrp1
and mrp3 genes were designed using PRIMER3 software
(free on-line access) and checked using Oligo Calculator
(free on-line access) and Primer-Blast (NCBI database).
The used sequences are listed in Table 2. rps19 and hprt
genes were used as non-regulated references for the
normalization of target gene expression [22,23]. Quanti-
tative RT-PCR was performed using fluorogenic SYBR
Green and the Sequence Detection System, Fast 7500
(Applied Biosystems). Data analysis was carried out
using the 7500 Fast System SDS Software Version
Table 1 Used siRNA sequences
Gene GenBank ID First strand Second strand
pgp NM_001003215 CGAACUGUUGUUUCUUUGA[dT][dT] UCAAAGAAACAACAGUUCG[dT][dT]
CUUCCGAACUGUUGUUUCU[dT][dT] AGAAACAACAGUUCGGAAG[dT][dT]
bcrp DQ222459.1 GCCCAGGAGUCAAUGUAAC[dT][dT] GUUACAUUGACUCCUGGGC[dT][dT]
CGAAUAAUACCUGUAGCUA[dT][dT] UAGCUACAGGUAUUAUUCG[dT][dT]
mrp1 NM_001002971 GAAAGAGGCUCCCUGGCAA[dT][dT] UUGCCAGGGAGCCUCUUUC[dT][dT]
GGAGUAUUCAGAAACGGAG[dT][dT] CUCCGUUUCUGAAUACUCC[dT][dT]
mrp3 XM_548204.2 GGCUAUGACGGAGAGCCAA[dT][dT] UUGGCUCUCCGUCAUAGCC[dT][dT]
UGUCUACGCUGCCUUGGGA[dT][dT] UCCCAAGGCAGCGUAGACA[dT][dT]
siRNA sequences used to pgp, bcrp, mrp1 and mrp3 genes silencing in canine mammary cancer cell lines. The canine (Canis lupus familiaris) pgp, bcrp, mrp1 and
mrp3 sequences were obtained from Gene Bank with accession numbers: NM_001003215, DQ222459.1, NM_001002971, XM_548204.2, respectively. The siRNA duplexes
were designed by http://www.sigmaaldrich.com/life-science/custom-oligos/sirna-oligos/sirna-design-service.html. The results were confirmed using two independent
algorithms: Dharmacon (OligoWalk) and Ambion.
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analyzed using comparative Ct method [24]. Relative
transcript abundance of the gene equals ΔCt values
(ΔCt = Ctreference – Cttarget). Relative changes in tran-
script were calculated as ΔΔCt values (ΔΔCt = 2-ΔCt).
The experiment was conducted three times.Flow cytometry determination of rhodamine-123
accumulation
Examined cancer cells (5 × 106 cells per ml) (control cells
and cells treated with pgp, bcrp, mrp1 and mrp3 –specific
siRNAs) were incubated for 1 h at 37°C in the 1 mmol of
rhodamine-123 (obtained from Sigma Aldrich, Germany).
After the incubation time, cells were washed twice, re-
suspended in ice cold PBS and kept at 4°C in the dark
until analysis in the flow cytometer. At least 50 000 cells
per sample were counted and analyzed by flow cytometry
(BD FACS Aria II, Becton Dickinson, USA). Cells shown
in forward scatter and side scatter were gated and
acquired through the fluorescence channel. The amount
of fluorescence was plotted as a histogram within the gate.
Data acquisition was performed using BD FACS DivaTable 2 Primers used for RT-qPCR







Primer sequences used in this study and their annealing optimal temperature and t
Primers were designed using PRIMER3 software (free on-line access) and checked u
Primers sequences are listed in Table 1. hprt and rps19 genes were used as non-regsoftware (Becton Dickinson, USA) to determine mean
fluorescence intensity values. This procedure has been
published before [25]. Results represent the average of at
least three independent experiments.
The overlay histogram was created using Flowing
Software (Turku University, Finland), available at www.
flowingsoftware.com.Cell viability assay (MTT-assay) and IC50 determination
Cell viability (metabolic activity of viable cells) was
quantified by MTT assay. Cells were seeded into 96-well
plate (Nunc Inc., Denmark) at the density which ensured
their 50-70% confluence at the day of experiment and: 1)
treated with vinblastine (at the following concentrations:
12.3, 36.9, 61.5, 123, 369, 615, 2 460, 4 920, 7 380 nmol),
cisplatin (at the following concentrations: 46.5, 83, 465,
830, 4 650, 8 300, 46 500, 83 000 166 000 nmol) or
cyclophosphamide (at the following concentrations: 425,
950, 1 900, 3 800, 19 000, 38 000 76 000 nmol) (all drugs
obtained from Sigma Aldrich, Germany), 2) transfected
with pgp, bcrp, mrp1 and mrp3 -specific siRNA and then










ime. The mRNA sequences of key genes were obtained from NCBI database.
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cyctotoxic drugs as given above. These concentrations of
anticancer drugs were determined in course of our
preliminary experiments (data not shown) and chosen
as appropriate to determine IC50 doses in all of the
examined cell lines.
Then, cells were incubated in 0.5 mg/ml tetrazolium
salt MTT diluted in phenol red-free RPMI 1640 medium
(Sigma Aldrich) for 4 hrs at 37°C. To complete
solubilization of the formazan crystals, 100 μl of DMSO
(Dimethyl sulfoxide, Sigma Aldrich) was added to
each well. Cells viability was quantified by measuring
photometric absorbance at 570 nm in multi well plate
reader Infinite 200 PRO Tecan™ (TECAN, Mannedorf,
Switzerland). All the samples were examined in tripli-
cate, each experiment was conducted seven times
(n = 21). Based on these results cytotoxicity was deter-
mined. It was expressed as a mean percentage decrease
relative to unexposed control ± S.D. Control values were
set at 100% viability. Cytotoxicity data were fitted to a
sigmoidal curve and a four parameter logistic model was
used to calculate IC50, which is the concentration of
agent which reduces cell growth by 50% under the
experimental conditions (increasing apoptosis, necrosis
or causing block in cell cycle). This analysis was
performed using GraphPad Prism 5.0 (San Diego, USA).
This method of IC50 analysis has been previously
published [26].
Apoptosis assay
The Annexin V-FITC and propidium iodide (PI) dual
staining was applied for apoptosis analysis. Control cells
(1) and cells treated with (2) anticancer drug at IC50 dose
and (3) transfected with pgp, bcrp, mrp1 and mrp3-
specific siRNA moreover treated with anticancer drug at
IC50 dose were harvested by trypsinization. These cells, as
well as the cells floating in medium (RPMI 1640 con-
taining 10% FBS) were stained with an Annexin V Kit
(Becton Dickinson, USA) according to the manufacturer’s
protocol. The cells then were analyzed by flow cytometry
(BD FACS Aria II, Becton Dickinson, USA) within 1 hr
after staining. Early apoptotic cells with exposed phos-
phatidylserine but intact cell membranes bound to
Annexin V-FITC however excluded PI. Cells in late apop-
totic stages were labeled with both Annexin V-FITC and
PI, whereas necrotic cells were labeled with PI only. All
samples were assayed in triplicate. The experiment was
conducted at least twice.
Statistical analysis
The analysis for statistical purposes was conducted using
Prism version 5.00 software (GraphPad Software, USA).
The one-way ANOVA and Tukey HSD (Honestly Signifi-
cant Difference) post-hoc test were applied as well asregression analysis. Determination of IC50 test has been
used. The p-value <0.05 was recognized as significant,
whereas, p-value <0.01 and p-value <0.001 as highly signifi-
cant. The data was expressed as means +/− S.D. For
molarity calculations, the Molarity Calculator (GraphPad,
USA) on-line platform was used.Results
PGP, BCRP, MRP1 and MRP3 are expressed in canine
mammary cancer cells and their expression level changes
due to anticancer drug in vitro treatment
RT-qPCR analysis revealed that all of the examined cell
lines express pgp, bcrp, mrp1 and mrp3 (Table 3). The
pgp expression ranged between 3.50 in CMT-U27 cell
line and 17.85 in CMT-W1 cell line. The bcrp expression
was the lowest in CMT-U309 cell lines (11.86) whereas
the highest in CMT-W2 cell line (36.00). The highest
expression of mrp1 was observed in CMT-W2 cell line
(24.02) whereas the lowest expression was noticed in
CMT-U27 cell line (7.50). CMT-W2 cell line exposed
the lowest expression of mrp3 (11.35). The highest
expression of mrp3 was detected in CMT-U309 cell line
(23.28).
Treatment of cancer cells using scrambled siRNA did
not cause any significant effect on examined gene
expression (Table 3), whereas treatment of these cells
with pgp, bcrp, mrp1 or mrp3 -specific siRNAs caused
significant decrease in transcript level of targeted genes
(the mostly significant effect was noticed in case of pgp
and mrp1) (Table 3). The efficacy of silencing reaction
was very high, as there was observed 88-99% decrease in
pgp transcript level, 14-100% in bcrp, 94-99% in mrp1
and 22-100% in mrp3 expression (Table 3).
Interestingly, we observed that pgp expression increased
significantly in all the examined cell lines after viblastine
and cisplatin treatment at IC50 doses, whereas decreased
after cyclophosphamide treatment at IC50 dose (Table 3).
Vinblastine treatment increased mrp1 expression in all of
the examined cell lines with exception of CMT-W2 cell
line where its expression increased also after treatment
with cyclophosphamide at IC50 dose (Table 3). In case of
bcrp, we observed increased tendency in its expression
after cyclophosphamide treatment and decreased in its
expression after vinblastine treatment at IC50 dose
(Table 3). We are as well able to point out the increase in
mrp3 expression in all the examined cell lines after
treatment with cisplatin at IC50 dose (Table 3).
Cancer cell treatment with pgp, bcrp, mrp1 and mrp3 –
specific siRNA decreases efflux pumps activity enhancing
rhodamine-123 accumulation
The rhodamine-123 efflux assay was conducted to confirm
our results of gene expression silencing and their functional
Table 3 Expression of pgp, bcrp, mrp1 and mrp3 in various experimental conditions
Efflux
pump
Sample Relative expression in cell lines
CMT-U27 CMT-U309 P114 CMT-W1 CMT-W2
PGP ctrl 3.50 9.20 5.00 17.85 16.42
pgp siRNA 0.45*** 0.10*** 0.50*** 0.80*** 0.16***
non-coding siRNA 3.44 9.10 5.10 7.750 16.31
vinblastine 9.50*** 16.20*** 14.70*** 19.56*** 21.52***
cisplatin 8.95*** 35.20*** 31.00*** 36.08*** 26.16***
cyclophosphamide 0.09*** 2.30** 0.22*** 0.08*** 2.87***
BCRP ctrl 19.84 11.86 23.52 23.70 36.00
bcrp siRNA 17.15** 2.77*** 2.77*** 10.46*** 0.00***
non-coding siRNA 19.00 11.20 22.90 23.00 36.18
vinblastine 14.84* 3.80*** 11.80*** 12.30*** 13.24*
cisplatin 30.50*** 22.16*** 40.34*** 36.57*** 37.23*
cyclophosphamide 23.32*** 33.53* 29.23*** 24.50* 41.72**
MRP1 ctrl 7.50 9.40 16.50 20.10 24.02
mrp1 siRNA 0.10*** 0.60*** 0.23*** 0.20*** 0.61***
non-coding siRNA 7.20 6.62 20.12 20.91 24.21
vinblastine 9.70*** 7.00*** 9.76*** 35.01* 30.20***
cisplatin 15.70*** 19.34** 21.84* 30.61*** 26.20**
cyclophosphamide 2.50** 0.09*** 3.32*** ↓0.40*** 6.04**
MRP3 ctrl 14.40 23.28 13.84 17.70 11.35
mrp3 siRNA 1.00*** 0.00*** 4.84*** 13.90** 7.15**
non-coding siRNA 13.87 21.99 13.09 17.10 10.99
vinblastine 14.20 21.97 13.12 17.50 9.78
cisplatin 15.60* 32.20*** 15.80* 21.30*** 14.09*
cyclophosphamide 14.99 24.09 14.25 18.01 11.72
Expression of efflux pumps in canine mammary cell lines in control conditions, after scrambled siRNA treatment and pgp, bcrp, mrp1 and mrp3 -specific siRNA
treatment as well as after treatment with vinblastine, cisplatin and cyclophosphamide at IC50 doses. p < 0.05 was marked as*, p < 0.01 was marked as **, and
p < 0.001 was marked as ***. One-way ANOVA followed by Tukey HSD post-hoc test were applied. Increase in expression was marked as red text, decreased in
expression was marked as green text, whereas no change in transcript level was marked as black text.
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mrp1 and mrp3 expression level, the rhodamine-;123 accu-
mulation significantly increased and that shows decreased
activity of the efflux pumps (Figure 1A, B). Treatment of
examined cells with scrambled siRNA did not cause any
significant effect (data not shown). We observed that
siRNA treatment of CMT-U27 caused significant but slight
effect on rhodamine-123 accumulation (mean fluorescence
related to rhodamine-123 accumulation in control cells was
97, whereas in siRNA treated cells it was between 108 and
110). In other cell lines the effect was higher (Figure 1), for
example in P114 cell line the mean fluorescence related to
rhodamine-123 accumulation in control cells was only 87
(the lowest, comparing to other cell lines) however, after
the treatment with bcrp-specific siRNA is was 128
(Figure 1). The highest effect of rhodamine-123 accumula-
tion after siRNA treatment was observed in CMT-W2 cell
line (148 after mrp3-specific siRNA treatment, 111 in
control conditions).Cancer cell treatment with siRNA specific to efflux pumps
decreases drug-resistance
The MTT assay of cells viability after treatment with
increasing doses of anticancer drugs showed significant
variations in IC50 doses between the examined cell
lines. All IC50 doses are listed in Table 4. Vinblastine
IC50 dose in CMT-U27 cell line was 1 588 nmol,
whereas after PGP and MRP1 knock-down it was only
203 nmol and 144 nmol, respectively (Table 4,
Figure 2A). In CMT-W2 cell line vinblastine IC50 was 9
434 nmol, whereas after pgp and mrp1 silencing it was
1264 nmol and 1248 nmol, respectively (Table 4). We
showed that after pgp and mrp1 silencing IC50 was
significantly lower in all the examined cell lines ranging
203–1391 nmol and 144–1248 nmol, respectively
(Table 4). Significant variations were also observed in
case of IC50 doses of cisplatin – the lowest IC50 dose
was in CMT-U27 cell line (5 669 nmol) (Figure 2B),
whereas the highest was in P114 cell line (42 944 nmol)
Figure 1 Activity of PGP, BCRP, MRP1 and MRP3. A.) Graph of mean fluorescence related to rhodamine-123 accumulation inside cancer cells
obtained using FACS Aria II (Becton Dickinson, USA). Error bars refer to S.D. p < 0.05 was marked as *. One-way ANOVA followed by Tukey HSD
post-hoc test was applied. B.) Representative overlay histograms of rhodamine-123 accumulation in CMT-U309 canine mammary cancer cells
(control, markered as green), and treated with pgp -specific siRNA (markerd as red). The overlay histograms were created using Flowing Software
(Turku University, Finland), www.flowingsoftware.com.
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all the examined cell lines after silencing of pgp, bcrp,
mrp1 and mrp3 (Table 4). Regarding cyclophosphamide,
we also noticed significant variations in IC50 values. It
was the lowest in CMT-W1 cell line (8 679 nmol), when
on the other hand the highest in CMT-W2 cell line
(25 698 nmol) (Table 4). Treatment of cells with bcrp-
specific siRNA decreased cyclophosphamide IC50 in all
of the examined cell lines (ranging between 765 and
5 705 nmol) (Table 4, Figure 2C).Table 4 IC50 doses of anticancer drugs in control conditions
Anticancer drug Condition IC50 in examined ce
CMT-U27
vinblastine ctrl 1 588
pgp siRNA 203***
bcrp siRNA 1 497
mrp1 siRNA 144***
mrp3 siRNA 1 330
cisplatin ctrl 5 669
pgp siRNA 2 203**
bcrp siRNA 3 300**
mrp1 siRNA 1 339**
mrp3 siRNA 303***
cyclophosphamide ctrl 9 599
pgp siRNA 8 432
bcrp siRNA 799***
mrp1 siRNA 8 762
mrp3 siRNA 8 802
IC50 doses [nmol] of anticancer drugs: vinblastine, cisplatin and cyclophosphamide
of efflux pumps expression. p < 0.05 was marked as *, p < 0.01 was marked as **, a
hoc test was applied.Cancer cell treatment with anticancer drug and siRNA
specific to efflux pumps increases apoptosis
The Annexin V assay was used to examine the influence of
pgp, bcrp, mrp1 and mrp3 expression knock-down on apop-
tosis induced by vinblastine, cisplatin and cyclophosphamide
(comparing to anticancer drug given as a single agent at
IC50 dose). Due to any changes in cells viability based on
transfection procedure were observed in MTT assay, this
kind of control has been omitted in apoptosis assay. We used
similar approach in our previous study [19].and after efflux pumps silencing
ll lines [nmol]
CMT-U309 P114 CMT-W1 CMT-W2
2 472 2 744 8 072 9 434
464*** 208*** 1 391*** 1 264***
2 417 2 572 8 002 7 346
772** 756** 1 747*** 1 248***
2 406 2 561 7 433 8 482
12 034 42 944 41 288 9 536
8 613** 5 000*** 32 663*** 6 707**
8 540** 17 699*** 11 228*** 8 177*
10 090* 20 348*** 29 132*** 5 695**
7 301** 13 565*** 11 163*** 7 177*
12 542 10 340 8 679 25 698
11 755 10 242 7 912 15 443
2 086*** 5705** 2 463** 765***
11 307 9 955 7 247 7 000
12 278 10 167 6 932 1 130
in canine mammary cancer cell lines in control conditions and after silencing
nd p < 0.001 was marked as ***. One-way ANOVA followed by Tukey HSD post-
Figure 2 Survival curves of CMT-U27 cells. Survival curves of CMT-U27 cells treated with increasing doses of vinblastine (A), cisplatin (B) and
cyclophosphamide (C). IC50 doses were determined in control conditions and after pgp, bcrp, mrp1 and mrp3 silencing. IC50 was calculated using
GraphPad Prism 5.0 (San Diego, USA).
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pgp and mrp1 -specific siRNA together with vinblastine
(at IC50 dose) significantly increased number of apoptotic
cells, compared to apoptosis caused by anticancer drug
which was given as a single agent (at the IC50 dose as well)
(Figure 3A). The most significant effect was pointed out in
CMT-W1 cell line: 25.35% and 17.45% increase in number
of apoptotic cells after pgp and mrp1 silencing and vinblast-
ine treatment, respectively (Figure 3). Similarly, in
CMT-W2 cell line 21.78% and 20.88% increase in number
of apoptotic cells was shown after pgp and mrp1 silencing
and vinblastine treatment, respectively (Figure 3).
In case of cisplatin treatment at IC50 dose, an increase
in number of apoptotic cells was noticed in each cell line
after silencing of all the efflux pumps: pgp, bcrp, mrp1 and
mrp3. The mostly significant result was observed in P114
cell line, where 40%, 41%, 42% and 40% increase in num-
ber of apoptotic cells (p < 0.001) was visible, respectively
(Figure 3B, D). In CMT-U309 cell line the highly signifi-
cant (p < 0.001) effect on apoptosis was as well as in case
of cisplatin treatment in cells transfected with siRNA spe-
cific to: pgp, bcrp and mrp3 (26.45%, 26.18% and 21.05%
increase in number of apoptotic cells, respectively),
whereas significant effect (p < 0.05) was observed in cells
transfected with mrp1 -specific siRNA (8.25% increase in
number of apoptotic cells) (Figure 3B).
In all the examined cell lines increase in number of
apoptotic cells related to cyclophosphamide treatment at
IC50 dose was undoubtedly visually recognized after bcrp
knock-down (Figure 3C). Additionally, in CMT-W2 cell
line the significant increase in number of apoptotic cells
was observed due to cyclophosphamide treatment follow-
ing transfection with bcrp, mrp1 and mrp3 -specific siRNA
(30%, 12.1% and 21%, respectively).
Discussion
Cancer cells retain the important mechanism of self-
protection through the activity of multiple drug resistancetransporters. The multidrug resistance is frequently associ-
ated with over-expression of two or more membrane
pumps that efflux anticancer drug from the cytoplasm.
This protects tumor cells against the drug effects and its
correlated molecular processes [8]. Expression of efflux
pumps is usually higher in tumors that originate from
tissues that normally show their expression and it is always
higher in the tumors than in normal cells [8]. Unfortu-
nately, the expression and role of proteins that mediate
drug resistance in canine cancer cells has not yet been
recognized. As increased efflux is such a significant con-
tributor to a multidrug resistance in cancer cells, current
research is aimed at blocking or inhibiting this specific
mechanism. That is why the aim of our study was to as-
sess expression of four the most important efflux pumps:
PGP, BCRP, MRP1 and MRP3 in canine mammary cancer
cells as well as to investigate their role in resistance to: cis-
platin, cyclophosphamide and vinblastine. Because treat-
ment of cancer cells with the use of classical inhibitors of
efflux pumps often fails [8,9], we used a novel approach,
that is: specific RNAi to knock-down their expression.
Examination of each efflux pump expression in control
conditions and after treatment with anticancer drug was
also quite a novel approach. We observed significant differ-
ences in pgp transcript level in control conditions and after
treatment with anticancer drug. In all of the examined cell
lines the pgp expression increased due to vinblastine and
cisplatin treatment whereas decreased due to cyclophos-
phamide treatment (Table 3). It ought to be outlined that
these results are in accordance with IC50 doses (Table 4).
In case of cisplatin treatment, expression of all four efflux
pumps increased, and thus, any relationship between their
transcript level and IC50 doses was very complicated to cal-
culate (Tables 3 and 4). We also observed that cyclophos-
phamide treatment caused increase in bcrp expression in all
of the examined cell lines. These results are in accordance
with previous findings that cytotoxic drugs can initiate or
increase expression of efflux pumps in cancer cells [27].
Figure 3 Apoptosis related to treatment with anticancer drugs. The number of apoptotic cells due to treatment with vinblastine
(A), cisplatin (B) and cyclophosphamide (C) at IC50 doses in control conditions and after efflux pumps silencing in canine mammary cancer cell
lines (CMT-U27, CMT-U309, P114, CMT-W1 and CMT-W2) assessed by the Annexin V/PI test (BD Bioscience, USA). All values were calculated versus
control conditions (spontaneous apoptosis in these cell lines). The numbers of apoptotic cells are represented as a percentages of Annexin
V-positive cells (obtained with FACS Aria II Becton Dickinson). The experiment has been conducted in three replicates. Error bars refer to S.D.
p < 0.05 was marked as *, p < 0.01 was marked as ** and p < 0.001 was marked as ***. One-way ANOVA followed by Tukey HSD post-hoc test was
applied. (D) The representative cytograms of P114 cell line double stained with Annexin V-FITC and propidium iodide (PI). The cytograms show
P114 cells in control conditions, after cisplatin treatment at IC50 dose and after pgp, bcrp, mrp1 and mrp3 -specific siRNA treatment followed by
cisplatin treatment at IC50 dose. On the cytograms are showed normal, early apoptotic, late apoptotic and necrotic cells. Left bottom quadrant
shows normal cells, top left quadrant shows necrotic cells (stained with PI only; damaged cell membrane but no phosphatydilserine exposure),
right bottom quadrant shows the early apoptotic cells (stained with Annexin V only; intact cell membrane) and top right quadrant shows cells in
late stage of apoptosis (stained with Annexin V and PI - phosphatydilserine exposure and damaged cell membrane).
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lates with response to anticancer therapy and patient follow
up [28]. Based on our results, we have come up with the
conclusion that examination of efflux pumps expression
before initiation of chemotherapy could help to predict
response to anticancer drugs and could be helpful in assess-
ment of their proper doses. However, more studies in this
field are required.
The RNAi gene silencing was highly successful (compar-
ing to our previously published studies [19,21]), reaching
even 100% of gene knock-down in case of bcrp in CMT-
W2 cell line and mrp3 in case of CMT-U309 cell line. The
results of gene knock-down were confirmed by the assay
with rhodamine-123 efflux. To assess whether efflux
pumps silencing has an influence on cancer cell suscepti-
bility to cytostatic drugs, the IC50 doses were determined
in transfected cells (Table 4, Figure 2). Our results showed
that vinblastine IC50 doses significantly decreased in all
the examined cell lines after pgp and mrp1 silencing
(Table 4). Examination of cisplatin IC50 in transfectedcells pointed that it was significantly lower in all of them
when compared to control cells (Table 4). In case of
cyclophosphamide, bcrp siRNA treatment significantly
decreased IC50 dose in all of the examined cell lines
(Table 4).
Comparison of IC50 doses of anticancer drugs given
in vitro and their maximum possible plasma concentra-
tions showed that in case of vinblastine the plasma con-
centration was much lower than the IC50 doses [29]. It
means that the examined cancer cell lines are vinblastine-
resistant and therefore this anticancer drug may be inef-
fective in canine mammary cancer treatment. However,
more studies in this field should be conducted. In case of
cisplatin, the IC50 doses in the three examined cell lines
(CMT-U27, CMT-U309 and CMT-W2) were lower than
the reachable plasma concentrations [30]. However, after
bcrp, mrp1 or mrp3 knock-down, the cisplatin IC50 doses
were similar or lower than the maximum possible plasma
drug concentration in all of the examined cell lines. It
means that knock-down of efflux pumps expression
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The IC50 doses of cyclophosphamide in all of the exam-
ined cell lines were significantly lower than its maximum
possible plasma concentration [31]. However, in all the
cases given above, targeting of ABC efflux pumps using
siRNA significantly decreased IC50 doses of anticancer
drugs. These results were also confirmed by apoptosis
assay (Figure 3).
In summary: knock-down of efflux pumps expression
during chemotherapy could allow decreased doses of anti-
cancer drugs thereby reducing the risk of their side effects.
However, more studies in this field are required as well as
large clinical trials to prove this hypothesis.
Our research is a completely new approach in the field
of veterinary oncology. The results show that targeting of
ABC-efflux pumps using RNAi can be promising strategy
in cancer treatment. However, these in vitro studies
should be confirmed using in vivo animal models.
Conclusions
The most important findings of our study are: (1) the ex-
pression level of efflux pump reflects the resistance to spe-
cific anticancer drug thus it should be assessed before the
initiation of chemotherapy; (2) in canine mammary cancer
PGP and MRP1 are responsible for vinblastine resistance,
PGP, BCRP, MRP1 and MRP3 are cisplatin transporters
whereas BCRP is a transporter of cyclophosphamide; (3)
treatment of cells using siRNA targeting efflux pumps sig-
nificantly increases cancer susceptibility to anticancer drug
and allows to decrease the effective dose of anticancer drug.
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